Category Archives: Uncategorized

Advocates Town Hall Meeting: Herpes advocates town hall meetings are open to patients, professionals, and those looking to get involved to make a difference. We’ll discuss Herpes Cure Advocacy urgent priorities, a 90 day action plan for new advocates, and ways to get more involved. Please submit questions in advance at info@herpescureadvocacy.com. Thursday, June 1Continue reading “Register: Herpes Advocates Town Hall Meeting June 1”

Herpes Clinical Pipeline AiCuris Non-Confidential Slide Deck May 2023: AiCuris planning for commercial launch of Priteliver 2025. Launch prep for Priteliver is ongoing. Innovative Molecules advances IM-250: The clinical trial center in Heidelberg, Germany has Phase 2 clinical trials are scheduled for 2024. The clinical phase 1 study investigates the safety, tolerability, and pharmacokinetics ofContinue reading “Progress for a Cure for Herpes Continues”

BDGene Therapeutics is a Chinese biotech company based in Shanghai. BDgene now has approval to run Phase 3 trials (held in China) on their gene therapy cure for HSV-1 keratitis. The gene editing treatment for viral keratitis (BD111), developed based on BDmRNA delivery patent technology, has completed 3 human clinical trials of IIT. It isContinue reading “Herpes Keratitis Cure advances to Phase 3 Clinical Trials in China”

Herpes Cure Advocacy celebrates a step forward on the path to the cure, treatment and prevention of Herpes. NIH has assembled a Multi-Council Working Group for Herpes Simplex Virus and are calling for input from field scientists and the general public. Herpes patients and field experts are excited to see this progress, an important winContinue reading “NIH forms Multi-Council Working Group for Herpes”

Herpes Cure Advocacy News HHS Listening Sessions: Two listening sessions were held this past week in an effort to gather insights for an addendum to the HHS 2020 STI Strategic Plan. Both patients and providers spoke with OIDP, NIH, and CDC stakeholders about their experiences and ideas for how to help cure, treat and preventContinue reading “Latest Updates on Herpes Cure Treatment and Prevention”

Mark your calendars! The HHS Office of Infectious Disease and HIV/AIDS Policy (OIDP) wants to hear from members of the STI community during two virtual listening sessions on April 4th and April 6th, 2023. OIDP is developing an addendum to the STI National Strategic Plan to include herpes simplex virus (HSV) types 1 and 2 in the United States.Continue reading “Advocacy Alert: Registration Open for OASH Listening Sessions”

Positive news abounds for the Aicuris team, and patients living with HSV, with the release of new results from their Phase three clinical trials for Pritelivir and initiation of a new clinical trial studying the use of Pritelivir in healthy patients. Pritelivir was found to be safe and well tolerated up to 600 mg followingContinue reading “Promising Progress in clinical trials for Pritelivir”

The Centers for Disease Control and Prevention (CDC), the Office of Science (OS) in late December 2022 issued a Broad Agency Announcement (BAA) for the competitive selection of research proposals, including a Request for Proposal (RFP) for a new serologic test for herpes simplex virus (HSV). Therefore, the goal of the RFP is to develop,Continue reading “CDC issues Request for Proposal to develop new serology test for Herpes Simplex Virus”

Hyundai Biosciences have applied for a clinical study in Korea to test the efficacy of CP-COVO3, a new candidate treatment for viral infections, on HPV. This antiviral agent, developed in Korea, has an innovative ‘viral removal’ mechanism applicable to all viruses, unlike existing antiviral agents that target only specific viruses. It is expected to openContinue reading “New Clinical Study for Broad spectrum anti-viral to treat HPV, Mpox, and possibly herpes”

December 21 2022, BioNTech announced they had dosed the first clinical trial participant. This is the first-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163. Company statement; “We aim to help address diseases with a high unmet medical need and of global health relevance, and we are combiningContinue reading “BioNTech New Clinical Trial for Herpes Vaccine begins”